Gilead Sciences Inc. has filed an investigational new drugapplication for the clinical evaluation in AIDS patients of GS393, its drug candidate for the treatment of humanimmunodeficiency virus infection, the company saidWednesday.

GS 393 is one of a series of small-molecule nucleotide analogsGilead of Foster City, Calif., is developing for the treatment ofcertain viral diseases.

Nucleotides are the building blocks of DNA and RNA, and can bechemically modified to inhibit the production of disease-causing proteins.

(c) 1997 American Health Consultants. All rights reserved.